Tofacitinib for the Treatment of Steroid-Induced Rosacea

Abstract

Tianhao Li,1 Henghong Wang,2 Caiying Wang,3 Pingsheng Hao1 1Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China; 2School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China; 3School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of ChinaCorrespondence: Pingsheng Hao, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shi-er-qiao Road, Chengdu, Sichuan Province, 610075, People’s Republic of China, Email [email protected]: Conventional treatment suffers from a dilemma of poor efficacy. The clinical use of Janus kinase (JAK) inhibitors in the treatment of steroid-induced rosacea has rarely been explored.Patients and Methods: We present a case of steroid-induced rosacea successfully treated with JAK inhibitor tofacitinib, with no adverse effects.Results: This case report of successful treatment shows a good clinical efficacy of JAK inhibitors tofacitinib in the treatment of SIR.Conclusion: JAK inhibitor tofacitinib may be a promising agent for the treatment with steroid-induced rosacea, especially for patients who have failed to conventional therapy.Keywords: steroid-induced rosacea, JAK inhibitors, tofacitinib

Keywords

• steroid-induced rosacea
• jak inhibitors
• tofacitinib